All In Biotech

Drug Trial Radar · NCT05270668

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

154

Actual

Start

Mar 29, 2022

Primary completion

Apr 16, 2026

Study completion Nov 16, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

Conditions

  • Diffuse Cutaneous Systemic Sclerosis
  • Interstitial Lung Disease

Interventions

  • TulisokibartDrug

    Tulisokibart administered at timepoints as directed by the protocol

  • Companion diagnostic ( CDx)Diagnostic test

    CDx+ or CDx-

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience an Adverse Event (AE)Time frame: Up to Week 50
  2. Number of Participants who Experience a Serious Adverse Event (SAE)Time frame: Up to Week 50
  3. Number of Participants who Discontinue due to an AETime frame: Up to Week 50
  4. Change from Baseline in the Annual Rate of Change in Forced Vital Capacity (FVC) at Week 50Time frame: Baseline and up to Week 50

Locations

95 sites in 20 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Scottsdale ( Site 4014)

    Phoenix, Arizona

  • Pacific Arthritis Care Center ( Site 4008)

    Los Angeles, California

  • Cedars Sinai Medical Center ( Site 4010)

    Los Angeles, California

  • UCLA School of Medicine ( Site 4006)

    Los Angeles, California

  • Stanford Health Care ( Site 4009)

    Palo Alto, California

  • National Jewish Health Medical Center ( Site 4015)

    Denver, Colorado

  • Yale University ( Site 4017)

    New Haven, Connecticut

  • MedStar Georgetown University Hospital ( Site 4005)

    Washington D.C., District of Columbia

  • Johns Hopkins Asthma and Allergy Center [Baltimore, MD] ( Site 4018)

    Baltimore, Maryland

  • Massachusetts General Hospital ( Site 4003)

    Boston, Massachusetts

  • Boston University School of Medicine ( Site 4021)

    Boston, Massachusetts

  • University of Michigan Hospital ( Site 4001)

    Ann Arbor, Michigan

  • Rutgers Robert Wood Johnson Medical School ( Site 4013)

    New Brunswick, New Jersey

  • Hospital For Special Surgery ( Site 4020)

    New York, New York

  • Cleveland Clinic Foundation ( Site 4019)

    Cleveland, Ohio

  • University of Toledo Medical Center ( Site 4002)

    Toledo, Ohio

  • University of Pittsburgh Medical Center ( Site 4016)

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina - PPDS ( Site 4004)

    Charleston, South Carolina

  • UT Physicians Rheumatology ( Site 4007)

    Houston, Texas

  • Froedtert and Medical College of Wisconsin ( Site 4012)

    Milwaukee, Wisconsin

  • Consultorios Médicos Dr. Doreski ( Site 4800)

    CABA, Buenos Aires, Argentina

  • Clínica Privada Independencia ( Site 4802)

    Munro, Buenos Aires, Argentina

  • Centro de Investigación Instituto Médico Río Cuarto ( Site 4801)

    Río Cuarto, Córdoba Province, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos ( Site 4803)

    Rosario, Santa Fe Province, Argentina

  • Royal Adelaide Hospital ( Site 4050)

    Adelaide, South Australia, Australia

  • St Vincents Hospital Melbourne ( Site 4051)

    Melbourne, Victoria, Australia

  • UZ Gent ( Site 4401)

    Ghent, Oost-Vlaanderen, Belgium

  • UZ Leuven ( Site 4402)

    Leuven, Vlaams-Brabant, Belgium

  • CHU de Liege ( Site 4400)

    Liège, Wallonne, Region, Belgium

  • University Of Alberta Hospital ( Site 4702)

    Edmonton, Alberta, Canada

  • St. Joseph's Health Care London ( Site 4701)

    London, Ontario, Canada

  • Mount Sinai Hospital [Toronto, Canada] ( Site 4700)

    Toronto, Ontario, Canada

  • Centro de especialidades médicas Vanguardia ( Site 4850)

    Temuco, Araucania, Chile

  • BIOCINETIC Ltda ( Site 4854)

    Santiago, Region M. de Santiago, Chile

  • Centro de Investigacion Clinica UC CICUC ( Site 4855)

    Santiago, Region M. de Santiago, Chile

  • Centro Internacional de Estudios Clinicos CIEC ( Site 4851)

    Santiago, Region M. de Santiago, Chile

  • Clinica Dermacross ( Site 4853)

    Vitacura, Region M. de Santiago, Chile

  • ONCOCENTRO APYS ( Site 4852)

    Viña del Mar, Valparaiso, Chile

  • Hopital Cochin ( Site 4203)

    Paris, France

  • CHU de Bordeaux. Hopital Pellegrin ( Site 4202)

    Bordeaux, Nord, France

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.